Q-omics provides the consensus-scored ZBTB20-AS4 profile across patient tissues and cancer cell-line models. ZBTB20-AS4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB20-AS4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZBTB20-AS4 RNA expression shows 18,026 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZBTB20-AS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB20-AS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB20-AS4 survival associations across molecular data types. ZBTB20-AS4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB20-AS4 RNA expression–survival associations across cancer types. High ZBTB20-AS4 expression shows unfavorable associations in THCA and CESC, but favorable associations in KIRC, MESO, LGG and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB20-AS4 RNA expression.
This table summarizes ZBTB20-AS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB20-AS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB20-AS4 shows lower tumor expression in THCA, KIRP, KIRC, LUSC, UCEC and HNSC. The THCA box plot shows higher ZBTB20-AS4 RNA expression in normal versus tumor tissue (log2 FC = −0.808, t-test p < 0.001).
This table shows molecular features associated with ZBTB20-AS4 in patient tissues and cancer cell lines. In patient samples, ZBTB20-AS4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
